MIGENIX Announces Initiation Of Rosacea Phase II Clinical Study By Partner, Cutanea Life Sciences

... MIGENIX Inc. (TSX: MGI; OTC: MGIFF) has been notified by Cutanea Life Sciences, Inc. ("Cutanea"), its development and commercialization partner for CLS001 (topical omiganan), of the initiation of a Phase II clinical study in the treatment of rosacea. This study is being conducted in the United States by Cutanea, and is expected to be completed by the end of 2007. [click link for full article] ...